Spots Global Cancer Trial Database for relapse leukemia
Every month we try and update this database with for relapse leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm | NCT06006403 | Acute Myeloid L... Blastic Plasmac... Relapse Leukemi... Refractory Leuk... | CD123 targeted ... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation | NCT03964922 | Relapse Leukemi... Allogeneic Stem... Immune Evasion,... | blood sample bone marrow sam... | 18 Years - 71 Years | Central Hospital, Nancy, France | |
| Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia | NCT03181815 | Acute Myeloid L... Relapse Leukemi... | Cladribine G-CSF Aclarubicin Cytarabine | 15 Years - 75 Years | Sun Yat-sen University | |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) | NCT03091933 | Hematologic Can... Relapse Leukemi... Relapsed Adult ... Relapsed Adult ... Relapsed CLL Relapsed Non Ho... Relapsed Hodgki... Relapsed Myelod... Relapsed Multip... | GLIDE | 18 Years - 65 Years | Ciusss de L'Est de l'Île de Montréal | |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) | NCT03091933 | Hematologic Can... Relapse Leukemi... Relapsed Adult ... Relapsed Adult ... Relapsed CLL Relapsed Non Ho... Relapsed Hodgki... Relapsed Myelod... Relapsed Multip... | GLIDE | 18 Years - 65 Years | Ciusss de L'Est de l'Île de Montréal | |
| Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy | NCT04282811 | Chronic Lymphoc... Relapse Leukemi... Refractory Leuk... | Venetoclax | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML | NCT06385808 | Relapse Leukemi... Refractory Acut... Conditioning Hematopoietic S... | MTBF regimen | 18 Years - 65 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation | NCT03964922 | Relapse Leukemi... Allogeneic Stem... Immune Evasion,... | blood sample bone marrow sam... | 18 Years - 71 Years | Central Hospital, Nancy, France | |
| Outcome Following Truncation of Asparaginase | NCT03987542 | Relapse Leukemi... | 1 Year - 18 Years | Aarhus University Hospital | ||
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm | NCT06006403 | Acute Myeloid L... Blastic Plasmac... Relapse Leukemi... Refractory Leuk... | CD123 targeted ... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | NCT05164042 | Relapse Leukemi... Refractory Leuk... | Allogeneic CD19... | 14 Years - 70 Years | Shenzhen University General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
